Gruenenthal Gmbh

Grunenthal Gmbh

Noxxon Pharma Ag

Park Therapeutics, Inc.

Gruenethal Gmbh

Gruenthal Gmbh

Medifron Dbt Inc.

Klaus Schiene

Gregor Bahrenberg

Thomas Christoph

Robert Frank

Derek John Saunders

Jean De Vry

Jeewoo Lee

Bernd Sundermann

Stefan Oberboersch

Ruth Jostock

Sven Kuehnert

Klaus Linz

Michael Haurand

Ulrich Jahnel

Melanie Reich

Elmar Josef Friderichs

Sven Frormann

Babette-Yvonne Koegel

Achim Kless

Stefanie Frosch

Nils Damann

Wolfgang Schroeder

Petra Bloms-Funke

Bernhard Lesch

Beatrix Merla

Yong-Soo Kim

Myeong-Seop Kim

Hannelore Stockhausen

Guenter Haase

Werner Guenter Englberger

Hagen-Heinrich Hennies

Stefan Schunk

Sven Kühnert

Tieno Germann

Michael Przewosny

Sabine Hees

Oswald K Zimmer

Saskia Zemolka

Johannes Schneider

Dagmar Kaulartz

Thomas Tzschentke

Paul Ratcliffe

Edward Bijsterveld

Anita Wegert

Thomas Koch

Ivars Graudums

Rene Michael Koenigs

Michael Franz-Martin Engels

Ilona Steigerwald

Michel Hamon

Silvia Reinartz

Sven Klussmann

Corinna Sundermann

Christian Maasch

Wolfgang Schröder

Florian Jakob

Florian Jarosch

Claudia Hinze

Ingo Konetzki

Ulrich Reinhold

Michael Engels

Axel Vater

Claudia Katharina Puetz

Marc Schiller

Sabine Karine Katrien Inghelbrecht

Robert Frank-Foltyn

Carsten Griebel

René Michael Koenigs

Babette-Yvonne Kögel

Steffen Helmling

Eva Wulsten

Stefan Oberbörsch

Clemens Gillen

Bernd Eschgfäller

Roger Carolus Embrechts

John Bothmer

Ulrich Feil

Guenther Haase

Mathias Bell

Elisabeth Moyroud

Sandra Stark

Thorsten Ruppert

Sabine Reinardy

Christopher Habermann

Hyung Chul Ryu

Jewoo Lee

Claudia Lefeber

Sabine Karine Inghelbrecht

Roger Carolus Augusta Embrechts

Günter Haase

Myeon-Seop Kim

Elmar Friiderichs

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from paracetamol and propacetamol.

Pharmaceutical composition comprising (1R,4R)-6'- fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro [cyclohexane-1,1&#x2032;-pyrano- [3,4,b ]indol] -4-amine and paracetamol or propacetamol

The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives

The use of tapentadol in the treatment of pain and/or pain chronification in a subject suffering from pain chronification and/or in the treatment of pain and inhibition of pain chronification in a subject suffering from pain and at risk of pain chronification, as well as the use of tapentadol for the treatment or inhibition of migraine.

Method of inhibiting chronification of pain

A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration.

Pharmaceutical combination

The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Combinations of certain analgesics with COX-II inhibitors, related pharmaceutical compositions, including advantageous galenical forms containing these combinations, and the use of such combinations in methods of treatment, in particular for the treatment of pain.

Combination of selected analgesics and COX-II inhibitors

A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, fenbufen, suprofen, pirprofen, indoprofen, tiaprofenic acid, oxaprozin, ibuproxam, flunoxaprofen, alminoprofen, naproxcinod, and the physiologically acceptable salts thereof.

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a salicylic acid component selected from the group consisting of acetylsalicylic acid, salicylic acid, salicylamide, ethenzamide, salsalate, dipyrocetyl, benorilate, diflunisal, guacetisal, and the physiologically acceptable salts thereof.

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-di methyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component

The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II

Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.

Substituted phenylureas and phenylamides as vanilloid receptor ligands

Pharmaceutical composition comprising (1r,4r)-6'-flouro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4&#x2032;,9&#x2032;-dihydro-3&#x2032;H-spiro[cyclohexane-1,1&#x2032;-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.

Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam

The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

Growing community of inventors

Juechen, Germany

Klaus Schiene